Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

Relationship between margin distance and local recurrence among patients undergoing wedge resection for small (≤2 cm) non–small cell lung cancer Kamran.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non- Small Cell Lung Cancer Ken Kodama, MD, Masahiko Higashiyama, MD, Jiro.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer Ernest Nadal,

Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer

A follow-up of integrated positron emission tomography/computed tomography after curative resection of non–small-cell lung cancer in asymptomatic patients

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Radical sublobar resection for small-sized non–small cell lung cancer: A multicenter study Morihito Okada, MD, PhD, Teruaki Koike, MD, PhD, Masahiko.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis Whitney S. Brandt, MD, Wanpu.

Meta-Analysis of Positron Emission Tomographic and Computed Tomographic Imaging in Detecting Mediastinal Lymph Node Metastases in Nonsmall Cell Lung Cancer

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm Hilâl Tekatli, MD, Saar van ’t Hof, MD, Esther.

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer Masatsugu Hamaji, MD, Mark S. Allen,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Maximum Standardized Uptake Value on FDG-PET Is a Strong Predictor of Overall and Disease-Free Survival for Non–Small-Cell Lung Cancer Patients after.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non–Small-Cell Lung Cancer Jung-Jyh Hung, MD,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non–small cell.

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Outcomes of Mediastinoscopy and Surgery with or without Neoadjuvant Therapy in Patients with Non-small Cell Lung Cancer Who are N2 Negative on Positron.

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko.

P3-252: Limited surgery for elderly patients with non-small cell lung cancer who have high risk for lobectomy: Comparison of the short- and the long-term.

Pulmonary Resection in Patients Aged 80 Years or Over with Clinical Stage I Non-small Cell Lung Cancer: Prognostic Factors for Overall Survival and Risk.

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43– 9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern.

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? Daniel J. Tandberg,

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

Nicholas Trakul, MD, PhD, Jeremy P

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Pulmonary Resection for Metastases from Colorectal Cancer

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Super Scan Using Positron Emission Tomography in Lung Cancer Patients

Farhood Farjah, MD, MPH, David R. Flum, MD, MPH, Scott D

Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States Megan E. Daly, MD, Julian R.

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and a Single- Station Involvement Jiro Okami, MD, PhD, Kinji Nishiyama, MD, PhD, Ayako Fujiwara, MD, Koji Konishi, MD, PhD, Takashi Kanou, MD, PhD, Toshiteru Tokunaga, MD, PhD, Teruki Teshima, MD, PhD, Masahiko Higashiyama, MD, PhD Journal of Thoracic Oncology Volume 8, Issue 11, Pages 1417-1424 (November 2013) DOI: 10.1097/JTO.0b013e3182a5097b Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 A flow chart of the patient selection. NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2013 8, 1417-1424DOI: (10.1097/JTO.0b013e3182a5097b) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 An example of complete response to radiotherapy for postoperative lymph node recurrence. PET scans of the whole body were obtained at baseline (A) and after 6 months of radiotherapy (B). PET, positron emission tomography. Journal of Thoracic Oncology 2013 8, 1417-1424DOI: (10.1097/JTO.0b013e3182a5097b) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Plots of the progression-free survival (A), local control (B), and overall survival (C) probabilities with 95% confidence intervals (dash lines) among patients who received radiotherapy for thoracic lymph node recurrence after surgery. Plots of the overall survival (D) probabilities in the patients who were both nonsymptomatic and with single involved lymph nodes station (n = 23, bold line) and the patients who were symptomatic or with multiple involved lymph nodes stations (n = 27, faint line). Journal of Thoracic Oncology 2013 8, 1417-1424DOI: (10.1097/JTO.0b013e3182a5097b) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Plots of the overall survival probabilities with 95% confidence intervals (dash lines) among patients who did not receive radiotherapy (n = 17). Journal of Thoracic Oncology 2013 8, 1417-1424DOI: (10.1097/JTO.0b013e3182a5097b) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions